Exploring the associations between low energy availability and mental health among university athletes: A systematic literature review.

J Sports SciAug 21, 2026 (epub)
Clinical ResearchPsychiatry

Siobhan Hegarty, Felicia Ovin, Nicola Keay et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review investigated the relationship between low energy availability (LEA) and mental health issues among university athletes. Eighteen studies were analyzed, revealing a high prevalence of LEA (41.7%-100%) and consistent associations with disordered eating behaviors. The review highlights the need for integrated care and early intervention to address these issues.

Key findings

  • LEA prevalence among university athletes ranged from 41.7% to 100%.
  • Cognitive dietary restraint and drive for thinness were key correlates of disordered eating.
  • Athletes with menstrual dysfunction had significantly higher disordered eating scores.
  • Early evidence suggests increased prevalence of anxiety and depression with LEA.

Why it matters

Understanding the link between low energy availability and mental health is crucial for developing effective interventions. Addressing these issues can improve both physical and mental health outcomes in university athletes.

Source

PubMed · PMID 42626975

Published in J Sports Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.